BNT324 + Docetaxel + Prednisone/prednisolone
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Trial Timeline
Mar 1, 2026 → Feb 1, 2031
NCT ID
NCT07365995About BNT324 + Docetaxel + Prednisone/prednisolone
BNT324 + Docetaxel + Prednisone/prednisolone is a phase 3 stage product being developed by BioNTech for Metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07365995. Target conditions include Metastatic Castration-resistant Prostate Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07365995 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer